A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

Phase 1 Terminated 30 enrolled Pfizer

Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18 years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer. Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be considered after discussion with and approval from sponsor.

Timeline

Start: 2021-10-07
Primary completion: 2023-10-17
Completion: 2023-10-17

Outcome

Outcome not reported

Stopped (Business): “Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities.”

Publications

Yan F, Cruz-Correa M, Specht J, Wang EW, Lu J, Soliman H, Jackson-Fisher A, Tang SY, Jiang S, Le Corre C, Li M, Sommerhalder D. A phase 1 study of PF-07260437, a B7-H4 x CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer. Invest New Drugs. 2026 May 22. doi: 10.1007/s10637-026-01614-2. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-07260437	Monoclonal antibody	100 ug	Subcutaneous